您的瀏覽器不支援 JavaScript 或已禁用 JavaScript。請啟用 JavaScript 以獲得最佳網站體驗。
最後更新日期:112-12-04
Therapeutical Class:Lincosamide antibiotics, inhibits bacterial protein synthesis by binding with 50S ribosomal subunits
Indication:Treatment of susceptible bacterial infections, mainly those caused by anaerobes, streptococci, pneumococci, and staphylococci.
Administraton:
Adults:
PO 150-450 mg q6-8h, max. 1.8g/day; taken with a full glass of water to avoid esophageal irritation.
IM or IV 1.2-2.7 g/day in 2-4 divided doses, to a max of 4.8 g/day.
Children: PO 8-20 mg/kg/day in 3-4 divided doses.
IM or IV:
<1 month: 15-20 mg/kg/day in 3-4 divided doses.
1 month: 20-40 mg/kg/day in 3-4 divided doses.
Dose adjustment in hepatic impairment.
Adverse Effect:Anorexia, nausea, vomiting, cramps, diarrhea, pseudomembranous colitis, rash.
Pregnancy Risk:B
Supply:Clincin XE “Clincin” Inj 300mg/2cc(克力欣注射液 南光)<02465>
Clindamycin XE “Clindamycin” Cap 150mg(克林達黴素膠囊 景德)<10895>